Patents by Inventor Tina Myers

Tina Myers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7655419
    Abstract: The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or the expression of the TBC protein and/or Rab1 protein. The invention also features methods of controlling viral replication, and agents useful in such methods.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: February 2, 2010
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Eli Lily and Company
    Inventors: Jeffrey Glenn, Ella Sklan, Kirk A. Staschke, Tina Myers Oakes
  • Publication number: 20080261906
    Abstract: The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or the expression of the TBC protein and/or Rab1 protein. The invention also features methods of controlling viral replication, and agents useful in such methods.
    Type: Application
    Filed: August 24, 2007
    Publication date: October 23, 2008
    Inventors: Jeffrey Glenn, Ella Sklan, Kirk Staschke, Tina Myers Oakes
  • Publication number: 20080125367
    Abstract: An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix.
    Type: Application
    Filed: September 4, 2007
    Publication date: May 29, 2008
    Inventors: Jeffrey Glenn, Tina Myers, John Glass